Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

TEM vs EXAS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EXAS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–0 Matrix Metrics)

EXAS Overall Winner 6-Pillar Tally: TEM 1 – 5 EXAS Matrix Metrics: TEM 0 – 7 EXAS

As of Nov 17, 2026, Exact Sciences Corp (EXAS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas EXAS carries 59.1/100 (HOLD) at $104.91 (N/M Forward P/E, -9.3% operating margin).

  • Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile EXAS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 75.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TEM vs EXAS
TEM NASDAQ
Tempus AI, Inc. Class A Common Stock
Services-Computer Programming, Data Processing, Etc.
$63.08
-2.59% 1D
Market Cap $13.1B
TTM Revenue $1.51B
Forward P/E N/M
Beta / 30D Vol 2.51β · 93% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 51.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $73.18 · SMA50: $72.83
EXAS NASDAQ Head-to-Head Winner
Exact Sciences Corp
Services-Medical Laboratories
$104.91
+0.95% 1D
Market Cap $19.8B
TTM Revenue $3.25B
Forward P/E N/M
Beta / 30D Vol -0.05β · 4% Vol
Unified Composite Score
59.1 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 57.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.8% over 20 days), RSI 76
RSI-14: 75.9 · SMA20: $103.57 · SMA50: $103.02

6-Pillar Scorecard Institutional Category Breakdown (TEM 1 – 5 EXAS)

Columns: Metric · TEM · EXAS
1. Valuation Multiples EXAS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.2x 6.1x
2. Growth & Scale EXAS
Revenue Growth (YoY) +23.1% +23.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.51B $3.25B
Market Cap $13.1B $19.8B
3. Profitability & Quality EXAS
Gross Margin 64.5% 69.7%
Operating Margin -18.5% -9.3%
Net Profit Margin -12.5% -6.4%
Return on Equity (ROE) -37.5% -8.7%
4. Balance Sheet & Cash Flow EXAS
Cash Generation (TTM) -$151M $71M EBITDA
Cash Flow Margin -10.0% 2.2% EBITDA Mgn
Net Cash / Leverage $841M Net Debt (2.86x D/E) $12.58 Book/Sh · -8.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EXAS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 99.3% (44th %ile) 0.2% (<1st %ile)
Put/Call OI Skew 0.49x (Call-Skewed) 0.21x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat TEM
OpEx & R&D Intensity 83.0% of Rev ($1.25B) 79.0% of Rev ($2.57B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Ecosystem & Network-Effect Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TEM (0) vs EXAS (7)
Institutional Metric TEM EXAS Criterion Row Edge
Market Capitalization
Scale
$13.1B $19.8B Larger Scale EXAS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+23.1% +23.1% Higher Growth Tie
Operating Margin (TTM)
Profitability
-18.5% -9.3% Higher Margin EXAS
Net Profit Margin
Profitability
-12.5% -6.4% Higher Margin EXAS
Return on Equity (ROE)
Capital Efficiency
-37.5% -8.7% Higher ROE EXAS
52-Week Range Position
Momentum
46% ($41–$89) 100% ($39–$105) Stronger Trend EXAS
Beta / 30D Volatility
Risk Regime
2.51β · 93% Vol -0.05β · 4% Vol Lower Realized Risk EXAS
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 59.1 / 100 (HOLD) Higher Composite EXAS
Trailing 12M Revenue (USD)
Operating Scale
$1.51B $3.25B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.5% 69.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.2x EV/Rev N/M PEG · 6.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$151M ($841M Net Debt (2.86x D/E)) $71M EBITDA ($12.58 Book/Sh · -8.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EXAS +23.25 pp
TEM: -21.68% · EXAS: +1.57%
3M Horizon EXAS +30.36 pp
TEM: -27.21% · EXAS: +3.15%
6M Horizon EXAS +87.94 pp
TEM: -31.43% · EXAS: +56.51%
1Y Horizon EXAS +87.94 pp
TEM: -31.43% · EXAS: +56.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TEM vs EXAS. Trailing 12-month operating profitability (TEM -18.5% vs EXAS -9.3%) and valuation multiples (TEM N/M vs EXAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TEM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.51B
Gross Margin64.5%
Op. Margin-18.5%
ROE / Fwd P/E-37.5% · N/M
EXAS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.25B
Gross Margin69.7%
Op. Margin-9.3%
ROE / Fwd P/E-8.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TEM BREAKDOWN
36d in phase · OBV DISTRIBUTION
Current IV 99.3%
IV Percentile 44th %ile
Put/Call OI Skew 0.49x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EXAS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EXAS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $64.76 · IV 84.1%

TEM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($6,476)

Compare $6,476 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 84.1% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $65 / $75 Bull Call Spread

Buy 1x $65C · Sell 1x $75C · 32d

Net Entry $365 Debit
T+5d @ +5% Move +$69 (+19%)
Max Risk / Buffer $365 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $55 Bull Put Spread

Sell 1x $60P · Buy 1x $55P · 32d

Net Entry $160 Credit
Max Credit / Yield +$160 (+47.1% RoM)
Max Risk / Buffer -9.8% Cushion ($340 Mgn)
5d Edge & Liquidity 68% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $55P / $70-$80C Seagull

Sell 1x $55P · Buy 1x $70/$80C · 32d

Net Entry $53 Debit
T+5d @ +5% Move +$151 (+18.8% RoM)
Max Risk / Buffer -15.1% Put Cushion ($803 Mgn)
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TEM Moat Profile Ecosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment 83.0% of Rev ($1.25B)
90D Engineering Disclosures 0 Published · AI Drug Discovery
EXAS Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $19.8B market capitalization and -9.3% operating margin.
OpEx & R&D Reinvestment 79.0% of Rev ($2.57B)
90D Engineering Disclosures 0 Published

Investor FAQ TEM vs EXAS Key Questions & Quantitative Answers

As of Nov 17, 2026, Exact Sciences Corp (EXAS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas EXAS carries 59.1/100 (HOLD) at $104.91 (N/M Forward P/E, -9.3% operating margin). Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile EXAS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 75.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EXAS leads the Growth & Scale pillar: TEM posts +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin), compared with EXAS at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $3.25B TTM revenue (69.7% gross margin, -9.3% operating margin). On trailing 12-month operating scale, TEM generates $1.51B in USD-normalized revenue versus $3.25B for EXAS. In operating R&D and SG&A reinvestment, TEM deploys 83.0% of Rev ($1.25B) (0 90-day corporate R&D disclosures) versus 79.0% of Rev ($2.57B) (0 disclosures) for EXAS.

EXAS screens cheaper on headline valuation multiples. TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin), whereas EXAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.1x EV/Revenue (2.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TEM (-37.5% ROE) versus EXAS (-8.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk). By comparison, EXAS carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.05β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.